Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AMC ENTERTAINMENT HOLDINGS, INC. (AMC) vs 10X Genomics Inc (TXG) Price & Performance

AMC ENTERTAINMENT HOLDINGS, INC.Trade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

AMC ENTERTAINMENT HOLDINGS, INC. vs 10X Genomics Inc — how do they compare? AMC ENTERTAINMENT HOLDINGS, INC. trades at $2.43 (market cap $2.14B), while 10X Genomics Inc trades at $59.15 (market cap $7.61B). The key difference: 10X Genomics Inc is far larger — about 3.6× AMC ENTERTAINMENT HOLDINGS, INC.'s market cap, and AMC ENTERTAINMENT HOLDINGS, INC. pays a 0.11% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.

AMCTXG
Market Cap
$2.14B$7.61B
Sector
MediaHealth
52-Week High
$3.15$58.57
52-Week Low
$0.95$11.34
Enterprise Value
$9.08B$7.14B
Dividend Yield
0.11%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AMC ENTERTAINMENT HOLDINGS, INC.

AMC trades at $2.42, down 6.56% today, yet maintains a bullish technical signal with strong recent earnings beats. The company reported record Q2 2026 revenue and EBITDA, driven by surging attendance and premium screen growth. However, negative net income and substantial debt of $4.01 billion highlight financial strain. Analyst consensus is a $3.00 price target with mixed ratings (32% Buy, 46% Hold).

The outlook hinges on sustained box office recovery and cash flow improvement, with management citing a potential cash-flow breakthrough. Key risks include high leverage, dependence on film slate success, and meme-stock volatility. Upside exists if operational momentum continues, but the negative equity position warrants caution.

10X Genomics Inc

TXG trades at $58.57, up 12.57% in 24 hours, reflecting strong momentum. The stock is technically bullish with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and revenue growth, yet remains unprofitable with a negative net income margin. Recent news highlights collaborations and acquisitions expanding its genomic capabilities.

Outlook is mixed; analyst consensus is neutral with a $46 price target below current levels, indicating caution despite recent beats. Key risks include sustained losses and competitive pressures, but operational cash flow growth and strategic expansions offer potential upside for patient investors focused on long-term biotech innovation.

Returns comparison

Trailing returns across standard periods

About AMC ENTERTAINMENT HOLDINGS, INC.

AMC Entertainment Holdings, Inc. operates as a holding company. The Company, through its subsidiaries, provides theatrical exhibition, movie screening, food distribution, online ticket booking, and other related services. AMC Entertainment offers movie theaters worldwide.

Read more on AMC

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG